FiercePharma

Bluebird scores $95M nest egg after selling second FDA priority review voucher to BMS

In quick succession, bluebird bio has cashed in a pair of speedy FDA review vouchers for nearly $200 million. Late this week, gene therapy player bluebird said it sold the second of two rare pediatric ...
Nasdaq

bluebird bio Enters into Advance Agreement to Sell Priority Review Voucher, if Granted, for $103 Million

SOMERVILLE, Mass.--(BUSINESS WIRE)-- bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it has entered into an agreement to sell a Rare Pediatric Disease Priority ...
FiercePharma

Argenx hands bluebird $102M for FDA speedy review voucher

Eyeing the next regulatory frontier in autoimmune disease, argenx is spending $102M on a speedy future review for its "pipeline-in-a-product" efgartigimod. Bluebird bio has sold argenx a rare ...
Nasdaq

bluebird (BLUE) to Boost Cash With Priority Review Voucher Sale

bluebird bio BLUE entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV). Upon completion of the transaction, bluebird will record $102 million from this ...
Business Wire

bluebird bio Sells Second Priority Review Voucher for $95 Million

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it has entered into a definitive agreement to sell its second Rare ...